Please login to the form below

Not currently logged in

Celgene wins orphan drug award at PMEA

Company is recognised for providing early access to Imnovid in multiple myeloma
PMEA 2014 Celgene rare diseases

Celgene was this week recognised for its work in rare diseases when it picked up the award for Rare Diseases and Orphan Drugs at PMEA 2014 on Wednesday evening.

Celgene was recognised for its work to build engagement around its cancer drug Imnovid (pomalidomide) in people with a rare blood cancer known as relapsed and refractory multiple myeloma.

The PMEA judges were particularly impressed with the way Celgene was able to provide patients in England with early access to the drug at launch via the Cancer Drugs Fund – a fund to pay for drugs not recommended for NHS reimbursement.

“The challenge was navigating the Cancer Drugs Fund and orchestrating a plan with a small, focused team – and they rose to it,” said the judges.

“Their work led to 212 patients being accepted by the Cancer Drugs Fund and an increase in life expectancy from three to 14 months - an inarguably strong outcome.”

Also recognised in the Rare Diseases and Orphan Drugs category at the London awards ceremony was Viropharma, which - alongside Havas Life Medicom - was highly commended for its campaign for Cinryze, a drug to prevent the rare genetic disorder hereditary angioedema.

Run by PMLiVE's publisher the PMGroup, the PMEA programme is specifically designed to recognise and commend excellence, best practice and innovation in local, European and international healthcare markets.

Article by
Thomas Meek

14th November 2014

From: Sales, Marketing, Healthcare



Featured jobs

Subscribe to our email news alerts


Add my company
Porterhouse Medical Group

Porterhouse Medical provides medical and scientific communication services to the pharmaceutical industry across the globe, with a focus on solutions...

Latest intelligence

How to get rep buy-in for multi-channel
How do you manage a team who may be resistant to change?...
Blog: Digital therapeutics: within our reach?
Digital therapeutics is a hot topic right now. By using digital technology to manage, treat or even prevent chronic conditions, digital therapeutics is promising to revolutionise healthcare. But is this...
figure 1
The valuable brand
Creating value beyond the pill is both possible and increasingly necessary...